Laura Panjwani

Articles

Myeloma Advances Result in More Remissions, Better QOL

November 3rd 2016

Sundar Jagannath, MD, discusses the importance of the standardization of a 3-drug regimen for newly diagnosed multiple myeloma, how the regimen may evolve going forward, and other novel agents on the horizon.

Large Gene Network Required to Predict Response to HER2-Targeted Therapy

November 2nd 2016

Lajos Pusztai, MD, DPhil, discusses findings that suggest it is unlikely that any single gene can predict response to targeted therapy for patients with HER2-positive breast cancer.

Using All Modalities Key to Expanding Immunotherapy Success in Oncology

November 1st 2016

While immunotherapy is currently only beneficial in select cancers, it is possible for this type of treatment to eventually work for all patients.

James Allison Says Rational Combinations Key to Immunotherapy Success in "Cold" Tumors

October 31st 2016

Immunotherapy has been a game changer in oncology, improving survival and providing long, durable responses in melanoma, lung, head and neck cancer, and others.

Novel Agents, Combinations Advance Second-Line RCC Care

October 27th 2016

The treatment paradigm of advanced renal cell carcinoma (RCC) has been rapidly changing. First, the FDA approved the combination of lenvatinib and everolimus in May 2016 as a treatment for patients with advanced RCC following prior antiangiogenic therapy.

Topalian Discusses the Evolution of PD-1/PD-L1 Inhibitors in Cancer Care

October 24th 2016

Suzanne L. Topalian, MD, discusses the development of PD-1/PD-L1 inhibitors, emerging biomarkers, and why a precision medicine approach is necessary to identify effective immunotherapy combination regimens.

Study Explores Mutation Discordance Between Primary, Metastatic Sites in CRC

October 20th 2016

Mutation discordance between primary and metastatic sites in colorectal cancer may occur more often than previously understood, opening the door for potential new therapeutic approaches to treating the disease.

Left-Sided CRC Survival Advantage May Be Dependent on Stage

October 19th 2016

The correlation between tumor location and improved survival varies based on stage of disease in patients with metastatic colorectal cancer.

Immunotherapy Combos, Novel Diagnostics Emerging in Melanoma

October 17th 2016

Jason Luke, MD, discusses some of the exciting research that is happening across the field of immunotherapy in melanoma, including combination strategies, novel agents, and next-generation diagnostics.

Improved Imaging, Classification Advance Sarcoma Care

October 17th 2016

The field of sarcoma may have reached a turning point, according to Kiran K. Turaga, MD.

Role for MRD in Myeloma Evolves as Novel Agents Increase Response

October 5th 2016

Shaji Kumar, MD, discusses the roles that the recently released updated consensus criteria by the International Myeloma Working Group and MRD testing will play going forward in multiple myeloma.

Targeted Treatments Still King in Kidney Cancer, Novel Combinations on the Horizon

October 4th 2016

In kidney cancer there are three “eras” in the history of treatment advances, said James Hsieh, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center.

Ibrutinib or FCR: Wierda Discusses First-Line Options for CLL

October 2nd 2016

There has been some debate over what should be the standard frontline treatment for patients with chronic lymphocytic leukemia: ibrutinib or chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab.

Novel Agents Hold Significant Promise in Treatment of AML

October 1st 2016

Jessica K. Altman, MD, discussed the potential of agents poised to transform the landscape of acute myeloid leukemia.

Expert Says Immunotherapy Not the "Magic Bullet" in Sarcoma

September 29th 2016

Katherine Thornton, MD, discusses the potential that immunotherapy agents could have in the field of sarcoma, as well as the role of genomic profiling in understanding the patients who may benefit from select treatments.

Expert Sheds Light on Issues With ASCO-CAP HER2 Guidelines

September 27th 2016

Michael F. Press, MD, PhD, discusses a retrospective study comparing the original FDA-approved criteria for HER2 gene amplification in breast cancer with the current ASCO-CAP guidelines, and exactly how the 2 sets of guidelines differ from one another.

Trabectedin, Eribulin Advance Sarcoma Care in Approved Indications and Beyond

September 24th 2016

Katherine Thornton, MD, discusses the use of trabectedin and eribulin both within and outside of their approved indications for soft tissue sarcoma.

New Classification System Reflects Improved Prognosis for HPV+ Oropharyngeal Cancer

September 22nd 2016

Researchers have created a new classification system for oropharyngeal cancer that is adjusted for the improved prognosis of patients with HPV-positive disease.

Pembrolizumab Approval Is Tip of the Iceberg for Immunotherapy in HNSCC

September 21st 2016

Barbara A. Burtness, MD, discussed the potential role for immunotherapy in frontline head and neck cancer, as well as the possible benefit of using it in combination with standard treatments, including radiation and chemotherapy.

Anti-CD19 CAR T-Cell Therapy Induces Significant Remission Rates in B-Cell ALL

September 19th 2016

Chimeric antigen receptor T-cell therapy targeting CD19 demonstrated a nearly 80% complete remission rate across relapsed/refractory B-cell acute lymphoblastic leukemia patients with multiple levels of disease burden.